B Group Inc’s Praxis Precision Medicines PRAX Stock Holding History

B Group Inc’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.1M	Hold	33,237	–	–	5.22%	7
2026 Q1	$10.7M	Hold	33,237	–	–	7.94%	3
2025 Q4	$9.8M	Buy	33,237 +1,737	+6%	+$323K	7.23%	5
2025 Q3	$1.67M	Sell	31,500 -3,500	-10%	-$170K	1.23%	15
2025 Q2	$1.47M	Buy	35,000 +16,000	+84%	+$609K	1.13%	15
2025 Q1	$720K	Buy	+19,000	New	+$1.19M	0.62%	16

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

B Group Inc's PRAX Position: Q2 2026 in Review

B Group Inc held its Praxis Precision Medicines (PRAX) position steady in Q2 2026 at 33,237 shares worth $11.1M. The position accounts for 5.22% of the portfolio, ranked #7.

B Group Inc first reported a position in PRAX in Q1 2025 and has held it in 6 quarters since. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

B Group Inc held 33,237 shares of Praxis Precision Medicines worth $11.1M as of Q2 2026.
B Group Inc left its Praxis Precision Medicines share count unchanged in Q2 2026.
Praxis Precision Medicines made up 5.22% of B Group Inc's portfolio in Q2 2026, its #7 holding.
B Group Inc first reported a position in Praxis Precision Medicines in Q1 2025 and has held it in 6 quarters since.
310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on B Group Inc's 13F filing for Q2 2026, filed 14 Aug 2026.